Sat.Feb 25, 2023 - Fri.Mar 03, 2023

article thumbnail

Digital natives: are pharma companies ready?

pharmaphorum

Engaging digitally native healthcare professionals requires companies to challenge existing business ethos and commit to the customer experience in an increasingly digital world.

98
article thumbnail

As clinical trials face a hiring crunch, here’s how research organizations can pivot

PharmaVoice

Staffing shortages are causing inefficiencies in clinical trials, but one leading CRO is finding ways to adapt.

105
105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv

Fierce Pharma

FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv kdunleavy Tue, 02/28/2023 - 18:55

FDA 140
article thumbnail

Why Congress should prioritize fixing the 340B program

PhRMA

Nearly all Americans nationwide agree: Lowering out-of-pocket costs for health care should be a top priority for policymakers. Luckily, there are commonsense policies Congress could implement to meaningfully address the cost burdens Americans face. These include things like making sure patients aren’t paying more for their medicines than their health insurance company or requiring first-dollar coverage, so insurance companies cover the cost of certain lifesaving medicines from day one of the pla

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

News Roundup: February 27 to March 3

Drug Topics

Your weekly roundup of the latest news from Drug Topics®.

187
187
article thumbnail

Opinion: How physician wellness programs keep doctors captive

STAT

The American College of Surgeons recently announced its new well-being initiative for surgeons. This wellness program has lofty goals: [The ACS] recognizes the need to foster well-being, resilience, and work-life integration for all surgeons, regardless of their career stage. Fostering the growth of both the surgical expertise and the person as a whole is paramount.

145
145

More Trending

article thumbnail

Celebrating 40 years of the Orphan Drug Act on Rare Disease Day

PhRMA

For over a decade, Rare Disease Day has been celebrated on February 28 to raise awareness and generate change for the more than 30 million patients in the U.S. living with a rare disease. This year’s Rare Disease Day is particularly special because this year also marks the 40 th anniversary of the Orphan Drug Act (ODA), allowing us to celebrate all the progress that’s come to patients because of it.

271
271
article thumbnail

Eli Lilly Slashing Insulin Prices, Capping Monthly Out of Pocket Costs For Many

Drug Topics

The pharmaceutical giant announced a 70% price reduction for most of its commonly sold insulin.

187
187
article thumbnail

Report: Obesity could cost the world over $4 trillion a year by 2035

STAT

The costs of obesity are projected to soar globally, in step with rising prevalence, according to a new report from the World Obesity Federation, the only group focused solely on tracking global obesity trends and a partner of the World Health Organization. Over half the world’s population will be either overweight or have obesity by 2035, the report projected, while the economic impact of a high BMI could reach $4.32 trillion annually, if current trends continue and policy inertia around

145
145
article thumbnail

DEA's proposed telehealth rules pull back COVID-era remote prescribing flexibilities

Fierce Healthcare

DEA's proposed telehealth rules pull back COVID-era remote prescribing flexibilities aburky Mon, 02/27/2023 - 14:17

131
131
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions

PhRMA

Health plans are increasingly using deductibles and coinsurance to shift more of the cost of care to chronically ill patients taking brand medicines. As data from IQVIA show, this alarming trend is especially burdensome for patients with cancer, who pay nearly 10X more on average per year for their medicines when they face deductibles and coinsurance versus patients with only fixed copays.

Insurance 243
article thumbnail

Rates of Sadness, Violence Increased in Teenage Girls

Drug Topics

A recent CDC report detailed the increased rates of sadness and violence among teenage girls.

187
187
article thumbnail

STAT Madness 2023

STAT

Welcome to STAT Madness, a bracket-style contest to find the best innovation in science and medicine. Click on each matchup for a short summary of each school’s pioneering research. Then pick your favorites. Help us crown a champ!

139
139
article thumbnail

Experts push to remove barriers for physician-owned hospitals

Fierce Healthcare

Experts push to remove barriers for physician-owned hospitals fdiamond Tue, 02/28/2023 - 14:42

Hospitals 128
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

PhRMA's Change Agents bring awareness and value of HBCUs and their impact to STEM

PhRMA

Historically Black Colleges and Universities (“HBCUs”), federally designated as any college or university established prior to 1964 with the principal mission of educating Black Americans, play a pivotal role in the education of people of color and in our society. In 1837, Cheyney University of Pennsylvania made history by becoming the first Historically Black College and University (HBCU) in the United States.

227
227
article thumbnail

CMS Not Willing To Expand Alzheimer's Drug Coverage

Drug Topics

CMS has no plans to change their coverage and approval process, which the Alzheimer's Association believes is standing between patients and treatment.

187
187
article thumbnail

The FDA has cleared the first home flu and Covid test — but its maker just declared bankruptcy

STAT

On Friday, the Food and Drug Administration issued an emergency authorization for the first at-home test that can detect flu and Covid-19 — but for the test’s maker, Lucira, the long-anticipated authorization may have taken too long. The company filed for bankruptcy on Feb. 22, directly blaming the “protracted” FDA authorization process for the over-the-counter combination test for its financial troubles.

FDA 132
article thumbnail

Lilly cuts insulin prices, caps out-of-pocket costs

Drug Store News

Lilly also will automatically cap out-of-pocket costs at $35 at participating retail pharmacies for people with commercial insurance using Lilly insulin.

Insurance 125
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

FDA-USPTO collaboration initiatives should be evidence-based, prioritize innovation

PhRMA

The United States Patent and Trademark Office (USPTO) and the U.S. Food and Drug Administration (FDA) are in the process of considering new collaboration initiatives aimed at biopharmaceutical patents. As outlined in a recent public statement and written comments , PhRMA appreciates the agencies seeking public participation on important innovation policy issues and we strongly support the agencies stated commitment to “ensuring our innovation system strikes the appropriate balance—encouraging me

FDA 207
article thumbnail

The Cost of Keeping Proper Inventory

Drug Topics

How can technology help pharmacists manage inventory—and the associated costs?

184
184
article thumbnail

Same patient, same drug, same insurer — coverage denied

STAT

Janice Morales-Ferrer is a planner. It’s helped her get ahead in her career and in raising three young kids. But it’s hard to plan when you’ve got a rare disease, especially one with no standard treatment regimen or predictable outcome. “I’m a data-driven person,” said the 46-year-old Boston area resident. “It’s frustrating for me to not be able to plan how long I can live for my kids.

article thumbnail

Hospitals' margins ticked downward in January but are still better off than much of 2022

Fierce Healthcare

Hospitals' margins ticked downward in January but are still better off than much of 2022 dmuoio Tue, 02/28/2023 - 15:07

Hospitals 124
article thumbnail

Eli Lilly slashes insulin prices by 70%, caps out-of-pocket costs in major access overhaul

Fierce Pharma

Eli Lilly slashes insulin prices by 70%, caps out-of-pocket costs in major access overhaul fkansteiner Wed, 03/01/2023 - 08:40

116
116
article thumbnail

DEA Proposes New Telemedicine Regulations

Drug Topics

The DEA is hoping to expand health care accessibility while also safeguarding from incorrectly prescribing medication.

184
184
article thumbnail

What the dogs of Chernobyl can teach us about life at the edge

STAT

You’d think an irradiated wasteland would be a poor place to make a home, but some animals beg to differ. Since the Chernobyl nuclear meltdown 37 years ago, both wild animals and free-roaming domesticated dogs have, to the surprise and delight of environmentalists, flocked to and flourished in the evacuated,1,000 square mile zone surrounding the plant.

119
119
article thumbnail

Cleveland Clinic closes Q4 strong but ultimately logs $1.2B net loss for 2022

Fierce Healthcare

Cleveland Clinic closes Q4 strong but ultimately logs $1.

122
122
article thumbnail

Walmart to open 28 new Walmart Health Centers

Drug Store News

This expansion will increase Walmart Health’s footprint into two new states, including Missouri and Arizona.

112
112
article thumbnail

New workflow for the analysis of mRNA therapeutics

European Pharmaceutical Review

Large RNA is rapidly emerging as a new class of therapeutics. Nowhere is this more publicly evident than in the development, regulatory approval, and efficacious use of mRNA‑based vaccines for COVID-19. Beyond the high-profile COVID-19 vaccines, mRNA therapeutics are crucial in applications such as protein replacement therapies and regenerative medicine.

Vaccines 111
article thumbnail

STAT+: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools

STAT

Genome editing summits are generally friendly, nerdy affairs, but for a moment at a Lisbon hotel last June, the conversation at the FASEB genome engineering conference grew tense. Tessera Therapeutics chief scientist Michael Holmes had just finished presenting a much-anticipated peek at a technology the company had previously said could “ revolutionize genetic medicine ” and “cure nearly any genetic disease.

119
119
article thumbnail

Physicians are twice as likely as the general population to attempt suicide, Medscape survey finds

Fierce Healthcare

Physicians are twice as likely as the general population to attempt suicide, Medscape survey finds aburky Fri, 03/03/2023 - 14:54

119
119
article thumbnail

Is the microbiome therapy hype up for a reckoning?

Pharmaceutical Technology

In the last decade, the idea of tapping into the gut has attracted much interest from investors and the public, but recent years have showed that a lot more work needs to be done before such treatments enter the mainstream. This is largely due to the FDA’s rigorous approach to the safety of microbiome therapeutics, which has manifested in clinical holds, resulting in delays that have dimmed the enthusiasm in the space in recent times.

FDA 111
article thumbnail

Regeneron, Sanofi's Kevzara becomes first biologic approved for polymyalgia rheumatica

Fierce Pharma

Regeneron, Sanofi's Kevzara becomes first biologic approved for polymyalgia rheumatica zbecker Wed, 03/01/2023 - 10:46

111
111
article thumbnail

STAT+: As a U.S. agency denies permits to import monkeys for research, industry starts pushing back

STAT

In a little-noticed move, the U.S. Fish and Wildlife Service recently began denying company requests to import certain monkeys from Cambodia for use in early-stage drug research. Now, the pharmaceutical industry is trying to push back by lobbying Congress. The National Association for Biomedical Research argues the situation is a “crisis,” with 60% of the supply of non-human primates “critical” to early-stage research now out of reach.

119
119